Abstract
Islet and pancreas transplantation are established and successful treatments for selected people with advanced diabetes. Whole organ pancreas transplant or islet transplant may be offered to patients with brittle diabetes at high risk, suffering hypoglycaemic unawareness. For people with advanced diabetes and associated nephropathy, combined pancreas kidney transplantation offers insulin-independence and improved quantity and quality of life. For optimal outcomes, donor selection is key and thus often approached highly conservatively. This is to avoid the risk of complications, particularly graft pancreatitis which may result in graft loss. Pancreas graft rejection is poorly defined and as such monitoring and surveillance of pancreas recipients remains a challenge. This chapter provides an overview of some of the key issues in pancreas transplantation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kelly WD, Lillehei RC, Merkel FK, Idezuki Y, Goetz FC. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery. 1967;61(6):827–37.
Kandaswamy R, Stock PG, Gustafson SK, Skeans MA, Urban R, Fox A, et al. OPTN/SRTR 2017 annual data report: pancreas. Am J Transplant. 2019;19(Suppl 2):124–83.
Karl RC, Scharp DW, Ballinger WF, Lacy PE. Transplantation of insulin-secreting tissues. Gut. 1977;18(12):1062–72.
Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343(4):230–8.
Lasker RD. The diabetes control and complications trial. Implications for policy and practice. N Engl J Med. 1993;329(14):1035–6.
Skupien J, Smiles AM, Valo E, Ahluwalia TS, Gyorgy B, Sandholm N, et al. Variations in risk of end-stage renal disease and risk of mortality in an international study of patients with type 1 diabetes and advanced nephropathy. Diabetes Care. 2019;42(1):93–101.
Accessed March 2013. http://odt.nhs.uk/pdf/advisory_group_papers/PAG/Standard_%20listing%20_criteria_summary.pdf
Lehmann R, Graziano J, Brockmann J, Pfammatter T, Kron P, de Rougemont O, et al. Glycemic control in simultaneous islet-kidney versus pancreas-kidney transplantation in type 1 diabetes: a prospective 13-year follow-up. Diabetes Care. 2015;38(5):752–9.
Gerber PA, Hochuli M, Benediktsdottir BD, Zuellig RA, Tschopp O, Glenck M, et al. Islet transplantation as safe and efficacious method to restore glycemic control and to avoid severe hypoglycemia after donor organ failure in pancreas transplantation. Clin Transplant. 2018;32(1).
Gruessner AC, Laftavi MR, Pankewycz O, Gruessner RWG. Simultaneous pancreas and kidney transplantation-is it a treatment option for patients with type 2 diabetes mellitus? An analysis of the international pancreas transplant registry. Curr Diab Rep. 2017;17(6):44.
Gruessner RW, Sutherland DE, Gruessner AC. Mortality assessment for pancreas transplants. Am J Transplant. 2004;4(12):2018–26.
Weiss AS, Smits G, Wiseman AC. Twelve-month pancreas graft function significantly influences survival following simultaneous pancreas-kidney transplantation. Clin J Am Soc Nephrol. 2009;4(5):988–95.
Sung RS, Zhang M, Schaubel DE, Shu X, Magee JC. A reassessment of the survival advantage of simultaneous kidney-pancreas versus kidney-alone transplantation. Transplantation. 2015;99(9):1900–6.
Access March 2019. https://optn.transplant.hrsa.gov/media/1116/03_pa_graft_failure_definition.pdf
Kandaswamy R, Stock PG, Skeans MA, Gustafson SK, Sleeman EF, Wainright JL, et al. OPTN/SRTR 2011 annual data report: pancreas. Am J Transplant. 2013;13(Suppl 1):47–72.
Troxell ML, Koslin DB, Norman D, Rayhill S, Mittalhenkle A. Pancreas allograft rejection: analysis of concurrent renal allograft biopsies and posttherapy follow-up biopsies. Transplantation. 2010;90(1):75–84.
Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006;355(13):1318–30.
Naziruddin B, Wease S, Stablein D, Barton FB, Berney T, Rickels MR, et al. HLA class I sensitization in islet transplant recipients: report from the Collaborative Islet Transplant Registry. Cell Transplant. 2012;21(5):901–8.
Kirchner VA, Finger EB, Bellin MD, Dunn TB, Gruessner RW, Hering BJ, et al. Long-term outcomes for living pancreas donors in the modern era. Transplantation. 2016;100(6):1322–8.
Robertson RP, Sutherland DE, Seaquist ER, Lanz KJ. Glucagon, catecholamine, and symptom responses to hypoglycemia in living donors of pancreas segments. Diabetes. 2003;52(7):1689–94.
Axelrod DA, Sung RS, Meyer KH, Wolfe RA, Kaufman DB. Systematic evaluation of pancreas allograft quality, outcomes and geographic variation in utilization. Am J Transplant. 2010;10(4):837–45.
Mittal S, Lee FJ, Bradbury L, Collett D, Reddy S, Sinha S, et al. Validation of the pancreas donor risk index for use in a UK population. Transpl Int. 2015;28(9):1028–33.
Blok JJ, Kopp WH, Verhagen MJ, Schaapherder AF, de Fijter JW, Putter H, et al. The value of PDRI and P-PASS as predictors of outcome after pancreas transplantation in a large European Pancreas Transplantation Center. Pancreas. 2016;45(3):331–6.
Accessed March 2019. https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/12300/transplant-activity-report-2017-2018.pdf
Brockmann JG, Vaidya A, Reddy S, Friend PJ. Retrieval of abdominal organs for transplantation. Br J Surg. 2006;93(2):133–46.
Maglione M, Ploeg RJ, Friend PJ. Donor risk factors, retrieval technique, preservation and ischemia/reperfusion injury in pancreas transplantation. Curr Opin Organ Transplant. 2013;18(1):83–8.
Stewart ZA, Cameron AM, Singer AL, Dagher NN, Montgomery RA, Segev DL. Histidine-tryptophan-ketoglutarate (HTK) is associated with reduced graft survival in pancreas transplantation. Am J Transplant. 2009;9(1):217–21.
Sollinger HW, Odorico JS, Becker YT, D’Alessandro AM, Pirsch JD. One thousand simultaneous pancreas-kidney transplants at a single center with 22-year follow-up. Ann Surg. 2009;250(4):618–30.
Stegall MD, Simon M, Wachs ME, Chan L, Nolan C, Kam I. Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine. Transplantation. 1997;64(12):1695–700.
Saudek F, Malaise J, Boucek P, Adamec M, Euro SPKSG. Efficacy and safety of tacrolimus compared with cyclosporin microemulsion in primary SPK transplantation: 3-year results of the Euro-SPK 001 trial. Nephrol Dial Transplant. 2005;20 Suppl 2:ii3–10, ii62.
Gruessner RW, Sutherland DE, Kandaswamy R, Gruessner AC. Over 500 solitary pancreas transplants in nonuremic patients with brittle diabetes mellitus. Transplantation. 2008;85(1):42–7.
Sibley RK, Sutherland DE. Pancreas transplantation. An immunohistologic and histopathologic examination of 100 grafts. Am J Pathol. 1987;128(1):151–70.
Sugitani A, Egidi MF, Gritsch HA, Corry RJ. Serum lipase as a marker for pancreatic allograft rejection. Transplant Proc. 1998;30(2):645.
Mittal S, Page SL, Friend PJ, Sharples EJ, Fuggle SV. De novo donor-specific HLA antibodies: biomarkers of pancreas transplant failure. Am J Transplant. 2014;14(7):1664–71.
Drachenberg CB, Odorico J, Demetris AJ, Arend L, Bajema IM, Bruijn JA, et al. Banff schema for grading pancreas allograft rejection: working proposal by a multi-disciplinary international consensus panel. Am J Transplant. 2008;8(6):1237–49.
Vendrame F, Pileggi A, Laughlin E, Allende G, Martin-Pagola A, Molano RD, et al. Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes. 2010;59(4):947–57.
Prieto M, Sutherland DE, Goetz FC, Rosenberg ME, Najarian JS. Pancreas transplant results according to the technique of duct management: bladder versus enteric drainage. Surgery. 1987;102(4):680–91.
Ryan EA, Shandro T, Green K, Paty BW, Senior PA, Bigam D, et al. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes. 2004;53(4):955–62.
Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med. 1998;339(2):69–75.
Mauer M, Fioretto P. Pancreas transplantation and reversal of diabetic nephropathy lesions. Med Clin North Am. 2013;97(1):109–14.
Browne S, Gill J, Dong J, Rose C, Johnston O, Zhang P, et al. The impact of pancreas transplantation on kidney allograft survival. Am J Transplant. 2011;11(9):1951–8.
Navarro X, Kennedy WR, Loewenson RB, Sutherland DE. Influence of pancreas transplantation on cardiorespiratory reflexes, nerve conduction, and mortality in diabetes mellitus. Diabetes. 1990;39(7):802–6.
Scheider A, Meyer-Schwickerath E, Nusser J, Land W, Landgraf R. Diabetic retinopathy and pancreas transplantation: a 3-year follow-up. Diabetologia. 1991;34(Suppl 1):S95–9.
La Rocca E, Fiorina P, di Carlo V, Astorri E, Rossetti C, Lucignani G, et al. Cardiovascular outcomes after kidney-pancreas and kidney-alone transplantation. Kidney Int. 2001;60(5):1964–71.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Johnson, P., Sharples, E., Sinha, S., Friend, P.J. (2021). Pancreas and Islet Transplantation: Pancreas and Islet Transplantation in Diabetes Mellitus. In: Hakim, N., Haberal, M., Maluf, D. (eds) Transplantation Surgery. Springer Specialist Surgery Series. Springer, Cham. https://doi.org/10.1007/978-3-030-55244-2_13
Download citation
DOI: https://doi.org/10.1007/978-3-030-55244-2_13
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-55243-5
Online ISBN: 978-3-030-55244-2
eBook Packages: MedicineMedicine (R0)